Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Annali Di Igiene : Medicina Preventiva E Di Comunita|December 23, 2020
Antibiotic resistance: is knowledge the only driver for awareness and appropriate use of antibiotics?D Zaniboni, E Ceretti, U Gelatti, et al.
Patient Education and Counseling|September 1, 2017
Does evidence support the use of mobile phone apps as a driver for promoting healthy lifestyles from a public health perspective? A systematic review of Randomized Control TrialsL Covolo, E Ceretti, M Moneda, et al.
Alimentary Pharmacology & Therapeutics|December 7, 2013
The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infectionL Covolo, S Bibert, F Donato, et al.
Occupational and Environmental Medicine|January 24, 2004
A mortality cohort study among workers in a graphite electrode production plant in ItalyD F Merlo, S Garattini, U Gelatti, et al.
Public Health|April 26, 2020
Willingness to pay for risky lifestyles: results from the Pay for Others (PAY4O) study, ItalyS Nembrini, E Ceretti, U Gelatti, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|November 7, 2003
Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control studyL Covolo, U Gelatti, M Metra, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita|October 27, 2006
Health-related quality of life in older people using benzodiazepines: a cross-sectional studyU Gelatti, F Samani, F Donato, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 3, 2009
Alcohol and coffee drinking and smoking habit among subjects with HCV infectionC Zani, F Donato, M Chiesa, et al.
Alimentary Pharmacology & Therapeutics|March 30, 2011
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis CG Fattovich, L Covolo, S Bibert, et al.
Journal of Viral Hepatitis|October 31, 2013
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysisV Di Marco, L Covolo, V Calvaruso, et al.
Pageof 2